In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to the standard 2-mg dose while allowing a longer treatment interval. An ...
Aflibercept 8 mg administered every 12 or 16 weeks demonstrated comparable improvements in best-corrected visual acuity and central subfield retinal thickness as 2-mg dose every 8 weeks in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results